Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...
(Biotech stocks that hit 52-week highs on May 20.) The topline data showed that filgotinib 200 mg achieved all primary endpoints in the study, inducing clinical remission at week 10 and maintaining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback